Trials / NCT07408232
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
Recruiting now Phase 1 / Phase 2 Drug / neuroprotection
- Sponsor
- Octant, Inc.
- Treatment
- Phase 1b/2: Cohort 1 - OCT-980 Tablet; Phase 1b/2: Cohort 2 - OCT-980 Tablet; Phase 1b/2: Cohort 3 - OCT-980 Tablet; Phase 1b/2: Cohort 4 - OCT-980 Tablet; Phase 1b/2: Cohort 5 - OCT-980 Tablet
- Gene
- RHO
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 18 participants
- Started
- 2026-03-10
- Main results expected
- 2028-11-01
- Results posted
- Not yet
- Record last updated
- 2026-09-24
What the study is testing
This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.
Where it runs
United States (2)
- Casey Eye Institute, Portland, Oregon (recruiting now)
- Retina Foundation of the Southwest, Dallas, Texas (recruiting now)